Adocia presented preclinical data on AdoXL Sema, designed for monthly injection
Adocia unveiled on November 16, 2026, at the ObesityWeek congress in Washington, preclinical data on AdoXL Sema, the application of its AdoXLong platform to semaglutide.
Obtained in rats and pigs, these results support, according to the company, monthly administration in humans. The measured weight loss is comparable to, and not greater than, that of the reference molecule.
Extended half-life in animals, weight loss comparable to semaglutide
In vitro, the intrinsic activity of AdoXL Sema is preserved, and its decrease in the presence of human albumin confirms its strong affinity for this protein. In rats, after subcutaneous injection, the half-life reaches 32 hours, more than 4 times that of semaglutide.
In farm pigs, it is 153 hours intravenously and 159 hours subcutaneously, more than 3 times that of the reference. Bioavailability is above 90%.
In obese rats followed over 26 days, the effect on weight is dose-dependent. At 30 nmol/kg, the reduction in weight gain is comparable to that of semaglutide, with a maximum decrease of approximately 5 to 6% of initial body weight.
Adocia has also obtained new in vitro results by applying AdoXLong to retatrutide: activity is preserved on the three targeted receptors (GLP-1, GIP and glucagon). For this second molecule, extended circulation remains an expectation, the company stating that AdoXL retatrutide "should" exhibit an extended in vivo circulation time.
Monthly injection and patent until 2046, subject to grant
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
"We intend to pursue its development with a view to clinical evaluation while favoring collaborations with pharmaceutical laboratories for their peptides," said Olivier Soula, chief executive officer and co-founder of the Lyon-based biotech.
The platform aims for a monthly injection with the same mode of use as Wegovy or Mounjaro, using fine 29G or finer needles. According to Adocia, a monthly formulation aims to reduce the discontinuation rate of these treatments, which it describes as very high from the first year.
The patent application, filed in November 2025, would, subject to grant, provide worldwide protection until 2046. The technology applies to innovative peptides as well as to biosimilars, including semaglutide, which has been off-patent since March 2026 in certain territories.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 0 millions d'euros
Quarterly revenue: 0 millions d'euros
Revenue growth: -97 %
Guidance from the release
« Au 30 septembre 2026, la Société disposait d'une trésorerie de 8,4 millions d'euros qui lui permettait de financer ses activités jusqu'au début du deuxième trimestre 2027 » ; « Cette opération, en prenant en compte l'utilisation complète de la convention d'avance en compte courant, ainsi que la réduction des coûts initiée par la Société depuis septembre 2026, permet d'étendre l'horizon de trésor
Risks mentioned
Dépendance critique au paiement d'étape de 20 millions de dollars conditionné à l'obtention de l'AMM de BioChaperone Lispro en Chine
Besoin de financement à court ou moyen terme et capacité à lever des fonds supplémentaires
Incertitudes des données cliniques futures et de l'évolution des marchés du diabète et de l'obésité
Opportunities identified
Paiement d'étape de 20 millions de dollars sous condition de l'approbation de BC Lispro en Chine avec redevances à deux chiffres
Accords de collaboration R&D monétisés avec les entreprises pharmaceutiques pour tester librement la technologie BioChaperone
Extension de l'horizon de trésorerie jusqu'au T1 2028 (voire 2029 si AMM obtenue) grâce à la levée de 7 millions d'euros
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.